Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genmab Moves On From Darzalex/Tecentriq Failure With Bispecifics Deal

Executive Summary

Genmab is planning for its post-Darzalex future by exploring bispecific immunotherapies in a collaboration with Immatics that should see it develop immunotherapies directed against three proprietary targets, with the option of two more.

Advertisement

Related Content

Deal Watch: BioCryst Shareholder Dissent Scuttles Planned Merger With Idera
Darzalex Solid Tumor And PD-(L)1 Combo Future Dashed
This Isn't The Big One: Darzalex Wins US Approval In First-Line Multiple Myeloma
Europe's Biopharma Sector Could Be In For Bumper Year
Immatics $58m Series E To Fund T-Cell Receptor-Based IO Therapies
Seattle Buys Into Future of Genmab ADC Deal

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123404

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel